Dyne Therapeutics, Inc.DYNNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank41
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P41
Within normal range
vs 3Y Ago
-0.7x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
PeriodValue
Q4 2025-23.19%
Q3 20254.14%
Q2 202510.57%
Q1 2025-25.56%
Q4 2024-13.01%
Q3 2024-36.02%
Q2 202430.14%
Q1 2024-124.35%
Q4 202330.82%
Q3 20239.06%
Q2 2023-18.62%
Q1 2023-60.69%
Q4 202231.80%
Q3 2022-38.49%
Q2 202239.08%
Q1 2022-80.77%
Q4 2021-4.14%
Q3 202141.60%
Q2 2021-150.91%
Q1 20218.20%
Q4 2020-68.75%
Q3 2020-62.40%
Q2 2020-0.32%
Q1 2020-81.56%
Q4 2019-34.88%
Q3 2019-22.87%
Q2 20190.00%
Q1 20190.00%
Q4 2017-69.00%
Q3 2017234.57%
Q2 2017-45.64%
Q1 2017451.85%
Q4 2016-91.87%
Q3 2016163.49%
Q2 2016-34.03%
Q1 2016191.83%
Q4 2015-164.40%
Q3 2015850.00%
Q2 2015161.82%
Q1 201583.73%